Overall survival (OS) can be improved in fit patients with chronic lymphocytic leukemia (CLL) if the minimal residual disease (MRD) end point is used to guide targeted therapy, according to results of a phase 3 trial. The study compared the combination of ibrutinib plus venetoclax with FCR (fludarabine, cyclophosphamide, rituximab).
The efficacy in this study “was superior to previous phase 3 CLL trials, indicating that duration guided by MRD is a new gold standard for CLL